Chemoprevention of Lung Cancer N. Van Zandwijk (Amsterdam, The Netherlands)
|   |
Tumours of the lung, larynx and pleura P. Boffetta (Lyon, France)
|   |
Tobacco K. Zarogoulidis (Thessaloniki, Greece)
|  |
Professional risks and environmental factors P. Boffetta (Lyon, France)
|   |
Screening R. M. Huber (Munich, Germany)
|   |
TNM clinical classification of lung carcinoma E. Brambilla (Grenoble, France)
|  |
Preneoplastic lesions A. Nicholson (London, United Kingdom)
|   |
Lung cancer biology E. Brambilla (Grenoble, France)
|   |
Clinical presentation of lung cancer S. G. Spiro (London, United Kingdom)
|   |
Staging: locoregional H-B. Ris (Lausanne, Switzerland)
|  |
Staging, distant metastases B. Bergman (Gothenburg, Sweden)
|   |
Diagnosis and staging of lung cancer: PET-scan M. Lonneux (Brussels, Belgium)
|   |
Endoscopic Treatment R. M. Huber (Munich, Germany)
|   |
Surgery for non-small cell lung cancer P. E. van Schil (Edegem, Belgium)
|   |
Neo(adjuvant) therapies combined with surgery in loco(regional) NSCLC A. Depierre (Besançon, France)
|   |
New potentials of radiotherapy and chemotherapy for lung cancer P. Van Houtte (Brussels, Belgium)
|   |
Systemic chemotherapy J-P. Sculier (Brussels, Belgium)
|   |
New drugs in lung cancer K. Zarogoulidis (Thessaloniki, Greece)
|  |
Survival prognostic factors for NSCLC T. Berghmans (Bruxelles, Belgium)
|   |
Chemotherapy vs best supportive care S. G. Spiro (London, United Kingdom)
|   |
Limited disease P. Van Houtte (Brussels, Belgium)
|   |
Extensive disease J-P. Sculier (Brussels, Belgium)
|   |
Brain metastases in small-cell lung cancer: prevention and treatment T. Berghmans (Bruxelles, Belgium)
|   |
Prognostic factors B. Bergman (Gothenburg, Sweden)
|   |